

RECEIVED
CENTRAL FAX CENTER

TEL:9198622260

P. 001

OCT 06 2005

Confidentiality Note:

The information contained in this facsimile message is confidential and its contents are intended to be legally privileged information solely for the use of the addressee. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, copying or other use of this message and its contents is strictly prohibited. If you have received this facsimile in error, please notify us immediately by telephone and return the original message to us at the address shown below via air courier service, the United States Postal Service or your national postal service (air mail). Thank You.

ALSTON&BIRD LLP3201 Beechleaf Court, Suite 600
Raleigh, NC 27604-1062919-862-2200
Fax: 919-862-2260**TELECOPY**

PLEASE DELIVER AS SOON AS POSSIBLE

DATE: October 6, 2005

TO: TC 1600**FROM:** Kelly J. Williamson
Patent Agent

In re: Lollar Confirmation No.: 5299
 Appl No.: 10/813,507 Group Art Unit: 1645
 Filed: 3/30/04
 For: NUCLEIC ACID AND AMINO ACID SEQUENCES ENCODING HIGH-
 LEVEL EXPRESSOR FACTOR VIII POLYPEPTIDES AND METHODS OF USE

Attachments

Preliminary Amendment(3 pages)

NO. OF PAGES: 4
(Including cover page)**OPERATOR:**

IF NOT RECEIVED PROPERLY, PLEASE NOTIFY ME IMMEDIATELY AT (919) 862-2200

USER CODE: LAKE
 CLIENT/MATTER: 007157/276516
 REQUESTED BY: Pam Lockley

FAX NUMBER: 571-273-8300

VOICE NUMBER:

OCT. -06' 05 (THU) 14:22

RECEIVED
CENTRAL FAX CENTER

TEL:9198622260

P. 002

OCT 06 2005

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.: 10/813,507

Confirmation No.: 5299

Applicant(s): Lollar

Filed: 3/30/04

Art Unit: 1645

Examiner: To be Assigned

Title: NUCLEIC ACID AND AMINO ACID SEQUENCES ENCODING HIGH-LEVEL
EXPRESSOR FACTOR VIII POLYPEPTIDES AND METHODS OF USE

Docket No.: 007157/276516

Customer No.: 00826

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PRELIMINARY AMENDMENT
37 CFR § 1.115

Sir:

Please enter this Preliminary Amendment before calculating the claim fee and amend the
above-identified application as follows:

Amendments to the Specification begin on page 2 of this paper.

Remarks begin on page 3 of this paper.